CRDF
Cardiff Oncology Inc

18,786
Mkt Cap
$131.26M
Volume
549,739.00
52W High
$4.56
52W Low
$1.48
PE Ratio
-2.80
CRDF Fundamentals
Price
$1.81
Prev Close
$1.92
Open
$1.92
50D MA
$2.11
Beta
1.47
Avg. Volume
867,754.17
EPS (Annual)
-$0.6864
P/B
2.89
Rev/Employee
$19,129.03
$130.35
Loading...
Loading...
News
all
press releases
What is Zacks Research's Forecast for CRDF FY2027 Earnings?
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Investment analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a note issued to investors on Monday, March 2nd...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Cardiff Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday...
MarketBeat·15d ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One research analyst...
MarketBeat·17d ago
News Placeholder
HC Wainwright Issues Optimistic Outlook for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Cardiff Oncology in a note issued to investors on Wednesday...
MarketBeat·20d ago
News Placeholder
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly...
MarketBeat·21d ago
News Placeholder
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price
Piper Sandler reduced their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday...
MarketBeat·22d ago
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) released its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18...
MarketBeat·22d ago
News Placeholder
Cardiff Oncology (CRDF) Expected to Announce Earnings on Thursday
Cardiff Oncology (NASDAQ:CRDF) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·28d ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat...
MarketBeat·1mo ago
News Placeholder
FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at Zacks Small Cap lifted their FY2027 earnings estimates for Cardiff Oncology in a report issued on Tuesday, February...
MarketBeat·1mo ago
<
1
2
...
>

Latest CRDF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.